Theranostics 2020; 10(1):437-461. doi:10.7150/thno.38366 This issue
Review
1. Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
2. Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed.
Keywords: Exendin-4, insulinoma, GLP-1, diabetes, PET, SPECT